Mukherjee and Vale's Myeloid teams up with David Liu's Prime Medicine in race against Tessera
Siddhartha Mukherjee and Ronald Vale’s Myeloid Therapeutics think it’s got the winning IP for RNA-based gene-insertion technology, and the biotech is teaming up with David Liu’s Prime Medicine to take it multitudes further than it could have done solo.
“There’s only really one other company working in this space that we know of, and that’s Tessera,” Myeloid CEO Daniel Getts told Endpoints News. Tessera has the backing of Moderna incubator Flagship Pioneering.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.